Person · CIK 1630299

Julie O'Neill

Director at Icon; Former Director at Achilles Therapeutics

Earlier: HOOKIPA Pharma, DBV Technologies and Alexion Pharmaceuticals

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$6.1M

Noticed on Form 144$508K

Bought on Form 4$0

Companies5

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Icon ICLR	Ordinary Shares	Directly	3,515	Aug 11, 2026 · Filing · EDGAR
Icon ICLR	Restricted Share Units into Ordinary Shares	Directly	1,324	Aug 10, 2026 · Filing · EDGAR
HOOKIPA Pharma	Common Stock	Directly	4,969	Oct 21, 2020 · Filing · EDGAR
HOOKIPA Pharma	Stock Option (Right to Buy) exercise $0.71, expires Jun 17, 2034, into Common Stock	Directly	49,000	Jun 17, 2024 · Filing · EDGAR
DBV Technologies	Warrant exercise $72.22, expires Jun 15, 2027, into Ordinary Shares	Directly	9,000	Jan 1, 2021 · Filing · EDGAR
DBV Technologies	Warrant exercise $45.54, expires Feb 7, 2028, into Ordinary Shares	Directly	7,000	Jan 1, 2021 · Filing · EDGAR
Alexion Pharmaceuticals	Common Stock, par value $.0001 per share	Directly	51,727	Feb 28, 2018 · Filing · EDGAR
Alexion Pharmaceuticals	Option to Purchase Common Stock exercise $131.25, expires Feb 28, 2027, into Common Stock, par value $.0001 per share	Directly	14,800	Feb 28, 2017 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)
Q3 2026	$150K	$150K
Q2 2025	—	$46K
Q1 2025	—	$53K
Q2 2024	—	$155K
Q2 2023	—	$103K
Q1 2018	$1M	Not machine-readable
Q3 2017	$2.2M	Not machine-readable
Q1 2017	$645K	Not machine-readable
Q3 2016	$82K	Not machine-readable
Q1 2016	$595K	Not machine-readable
Q3 2015	$111K	Not machine-readable
Q1 2015	$1.3M	Not machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Icon ICLR · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 4 notices
Aug 11, 2026	915 · ~$150K	Aug 11, 2026	Sold as noticed Sold 915 in 4 sales, Aug 11 to Aug 11 · $150K Form 4	Filing · EDGAR
May 23, 2025	363 · ~$46K	May 23, 2025	Not sold within 90 days	Filing · EDGAR
May 23, 2024	490 · ~$155K	May 23, 2024	Not sold within 90 days	Filing · EDGAR
May 22, 2023	484 · ~$103K	May 22, 2023	Not sold within 90 days	Filing · EDGAR
Achilles Therapeutics · Citigroup Capital Markets · No 10b5-1 plan stated · 1 notice
Feb 5, 2025	38,750 · ~$53K	Feb 4, 2025	Not sold within 90 days	Filing · EDGAR
Sales without a matching Form 144 · 27 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 686 at $118.61 on Feb 28, 2018 · $81K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 939 at $120.72 on Feb 27, 2018 · $113K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 4,787 at $116.31 on Feb 8, 2018 · $557K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 2,119 at $117.26 on Feb 5, 2018 · $248K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 650 at $145.81 on Sep 5, 2017 · $95K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 600 at $145.64 on Sep 5, 2017 · $87K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 672 at $147.00 on Sep 5, 2017 · $99K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 1,841 at $145.81 on Sep 5, 2017 · $268K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 612 at $142.00 on Aug 31, 2017 · $87K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 11,160 at $140.00 on Aug 28, 2017 · $1.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 651 at $133.80 on Mar 2, 2017 · $87K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 664 at $131.70 on Feb 28, 2017 · $87K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 910 at $131.20 on Feb 27, 2017 · $119K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 2,795 at $125.69 on Feb 6, 2017 · $351K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 650 at $126.29 on Sep 2, 2016 · $82K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 651 at $149.55 on Mar 2, 2016 · $97K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 663 at $138.91 on Feb 29, 2016 · $92K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 755 at $138.02 on Feb 8, 2016 · $104K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 23 at $139.75 on Feb 8, 2016 · $3K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 530 at $141.54 on Feb 5, 2016 · $75K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 499 at $142.33 on Feb 5, 2016 · $71K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 351 at $143.46 on Feb 5, 2016 · $50K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 352 at $144.53 on Feb 5, 2016 · $51K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 348 at $145.55 on Feb 5, 2016 · $51K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 647 at $171.76 on Sep 2, 2015 · $111K	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 6,565 at $180.34 on Mar 2, 2015 · $1.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Alexion Pharmaceuticals: Sold 795 at $171.15 on Feb 10, 2015 · $136K	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Icon ICLR Director · filings 2023 to 2026 · sold $150K · $455K noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 11, 2026	Open-market or private sale	−95	$162.72	$15K	4,335 direct	Filing · EDGAR
Aug 11, 2026	Open-market or private sale	−105	$163.77	$17K	4,230 direct	Filing · EDGAR
Aug 11, 2026	Open-market or private sale	−642	$164.47	$106K	3,588 direct	Filing · EDGAR
Aug 11, 2026	Open-market or private sale	−73	$165.51	$12K	3,515 direct	Filing · EDGAR
Aug 10, 2026	Option or RSU exercised or converted	+1,732			4,430 direct	Filing · EDGAR
Aug 10, 2026	Option or RSU exercised or converted Restricted Share Units	−1,732			0 direct	Filing · EDGAR
Aug 10, 2026	Grant or award from the company Restricted Share Units	+1,324			1,324 direct	Filing · EDGAR

Achilles Therapeutics Former Director · filings 2025 to 2025 · $53K noticed on Form 144

No transactions in the filings read; Form 144 notices are listed above.

HOOKIPA Pharma Director · filings 2019 to 2024

Date	Transaction	Shares	Held after	Source
Jun 17, 2024	Grant or award from the company Stock Option (Right to Buy)	+49,000	49,000 direct	Filing · EDGAR
Jun 9, 2023	Grant or award from the company Stock Option (Right to Buy)	+26,000	26,000 direct	Filing · EDGAR
Jun 30, 2022	Grant or award from the company Stock Option (Right to Buy)	+20,000	20,000 direct	Filing · EDGAR
Jun 1, 2021	Grant or award from the company Stock Option (Right to Buy)	+9,600	9,600 direct	Filing · EDGAR
Oct 21, 2020	Grant or award from the company	+4,969	4,969 direct	Filing · EDGAR
Jun 18, 2020	Grant or award from the company Stock Option (Right to Buy)	+9,600	9,600 direct	Filing · EDGAR
Dec 18, 2019	Grant or award from the company Stock Option (Right to Buy)	+9,600	9,600 direct	Filing · EDGAR
Apr 17, 2019	Grant or award from the company Stock Option (Right to Buy)	+6,924	6,924 direct	Filing · EDGAR

DBV Technologies Director · filings 2021 to 2021

No transactions in the filings read; Form 144 notices are listed above.

Alexion Pharmaceuticals EVP. Global Operations · filings 2015 to 2018 · sold $6M

Date	Transaction	Shares	Price	Value	Held after	Source
Feb 28, 2018	Grant or award from the company	+8,940			51,727 direct	Filing · EDGAR
Feb 28, 2018	Open-market or private sale	−686	$118.61	$81K	42,787 direct	Filing · EDGAR
Feb 27, 2018	Open-market or private sale	−939	$120.72	$113K	43,473 direct	Filing · EDGAR
Feb 8, 2018	Open-market or private sale	−4,787	$116.31	$557K	44,412 direct	Filing · EDGAR
Feb 6, 2018	Grant or award from the company	+21,489			41,699 direct	Filing · EDGAR
Feb 6, 2018	Grant or award from the company	+7,500			49,199 direct	Filing · EDGAR
Feb 5, 2018	Open-market or private sale	−2,119	$117.26	$248K	20,210 direct	Filing · EDGAR
Sep 5, 2017	Sale under a 10b5-1 plan	−1,841	$145.81	$268K	24,251 direct	Filing · EDGAR
Sep 5, 2017	Sale under a 10b5-1 plan	−672	$147.00	$99K	23,579 direct	Filing · EDGAR
Sep 5, 2017	Sale under a 10b5-1 plan	−600	$145.64	$87K	22,979 direct	Filing · EDGAR
Sep 5, 2017	Open-market or private sale	−650	$145.81	$95K	22,329 direct	Filing · EDGAR
Aug 31, 2017	Sale under a 10b5-1 plan	−612	$142.00	$87K	26,092 direct	Filing · EDGAR
Aug 28, 2017	Sale under a 10b5-1 plan	−11,160	$140.00	$1.6M	26,704 direct	Filing · EDGAR
Mar 2, 2017	Open-market or private sale	−651	$133.80	$87K	37,864 direct	Filing · EDGAR
Feb 28, 2017	Open-market or private sale	−664	$131.70	$87K	31,015 direct	Filing · EDGAR
Feb 28, 2017	Grant or award from the company	+7,500			38,515 direct	Filing · EDGAR
Feb 28, 2017	Grant or award from the company Option to Purchase Common Stock	+14,800			14,800 direct	Filing · EDGAR
Feb 27, 2017	Open-market or private sale	−910	$131.20	$119K	31,679 direct	Filing · EDGAR
Feb 6, 2017	Open-market or private sale	−2,795	$125.69	$351K	32,589 direct	Filing · EDGAR
Sep 2, 2016	Open-market or private sale	−650	$126.29	$82K	35,384 direct	Filing · EDGAR
Mar 2, 2016	Open-market or private sale	−651	$149.55	$97K	36,034 direct	Filing · EDGAR
Feb 29, 2016	Open-market or private sale	−663	$138.91	$92K	36,685 direct	Filing · EDGAR
Feb 26, 2016	Grant or award from the company	+7,000			37,348 direct	Filing · EDGAR
Feb 26, 2016	Grant or award from the company Option to Purchase Common Stock	+31,000	$140.16	$4.3M	31,000 direct	Filing · EDGAR
Feb 8, 2016	Open-market or private sale	−23	$139.75	$3K	31,103 direct	Filing · EDGAR
Feb 8, 2016	Open-market or private sale	−755	$138.02	$104K	30,348 direct	Filing · EDGAR
Feb 5, 2016	Open-market or private sale	−348	$145.55	$51K	32,858 direct	Filing · EDGAR
Feb 5, 2016	Open-market or private sale	−352	$144.53	$51K	32,506 direct	Filing · EDGAR
Feb 5, 2016	Open-market or private sale	−351	$143.46	$50K	32,155 direct	Filing · EDGAR
Feb 5, 2016	Open-market or private sale	−499	$142.33	$71K	31,656 direct	Filing · EDGAR
Feb 5, 2016	Open-market or private sale	−530	$141.54	$75K	31,126 direct	Filing · EDGAR
Feb 4, 2016	Grant or award from the company	+11,763			33,206 direct	Filing · EDGAR
Sep 2, 2015	Open-market or private sale	−647	$171.76	$111K	21,443 direct	Filing · EDGAR
Mar 2, 2015	Open-market or private sale	−6,565	$180.34	$1.2M	22,090 direct	Filing · EDGAR
Feb 27, 2015	Open-market or private sale	+5,100			28,655 direct	Filing · EDGAR
Feb 27, 2015	Grant or award from the company Option to Purchase Common Stock	+24,400			24,400 direct	Filing · EDGAR
Feb 10, 2015	Open-market or private sale	−795	$171.15	$136K	23,555 direct	Filing · EDGAR
Feb 5, 2015	Grant or award from the company	+4,350			24,350 direct	Filing · EDGAR

All 35 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Aug 12, 2026	Form 4	Icon ICLR	Filing · EDGAR
Aug 11, 2026	Form 144	Icon ICLR	Filing · EDGAR
Mar 18, 2026	Form 3	Icon ICLR	Filing · EDGAR
May 23, 2025	Form 144	Icon ICLR	Filing · EDGAR
Feb 6, 2025	Form 144	Achilles Therapeutics	Filing · EDGAR
Jun 18, 2024	Form 4	HOOKIPA Pharma	Filing · EDGAR
May 23, 2024	Form 144	Icon ICLR	Filing · EDGAR
Jun 9, 2023	Form 4	HOOKIPA Pharma	Filing · EDGAR
May 22, 2023	Form 144	Icon ICLR	Filing · EDGAR
Jul 1, 2022	Form 4	HOOKIPA Pharma	Filing · EDGAR
Jun 4, 2021	Form 4	HOOKIPA Pharma	Filing · EDGAR
Jan 11, 2021	Form 3	DBV Technologies	Filing · EDGAR
Oct 23, 2020	Form 4	HOOKIPA Pharma	Filing · EDGAR
Jun 19, 2020	Form 4	HOOKIPA Pharma	Filing · EDGAR
Jan 3, 2020	Form 4	HOOKIPA Pharma	Filing · EDGAR
Apr 24, 2019	Form 4	HOOKIPA Pharma	Filing · EDGAR
Apr 17, 2019	Form 3	HOOKIPA Pharma	Filing · EDGAR
Mar 2, 2018	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Mar 1, 2018	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Feb 8, 2018	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Feb 7, 2018	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Sep 5, 2017	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Aug 30, 2017	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Mar 6, 2017	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Mar 1, 2017	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Feb 8, 2017	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Sep 2, 2016	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Mar 4, 2016	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Mar 1, 2016	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Feb 8, 2016	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Sep 10, 2015	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Mar 3, 2015	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Feb 12, 2015	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Feb 9, 2015	Form 4	Alexion Pharmaceuticals	Filing · EDGAR
Jan 9, 2015	Form 3	Alexion Pharmaceuticals	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.